2.82
Schlusskurs vom Vortag:
$2.78
Offen:
$2.8
24-Stunden-Volumen:
75,577
Relative Volume:
0.55
Marktkapitalisierung:
$38.21M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-70.20M
KGV:
-0.0629
EPS:
-44.82
Netto-Cashflow:
$-50.66M
1W Leistung:
-2.76%
1M Leistung:
-7.84%
6M Leistung:
+17.99%
1J Leistung:
-64.35%
Onkure Therapeutics Inc Stock (OKUR) Company Profile
Firmenname
Onkure Therapeutics Inc
Sektor
Branche
Telefon
(720) 307-2892
Adresse
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Vergleichen Sie OKUR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
OKUR
Onkure Therapeutics Inc
|
2.82 | 37.66M | 0 | -70.20M | -50.66M | -44.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-30 | Eingeleitet | Evercore ISI | Outperform |
| 2024-12-05 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-10 | Eingeleitet | Oppenheimer | Outperform |
| 2023-12-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-15 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-15 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-12-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-12-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2023-12-14 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-12-14 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-12-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-11-15 | Eingeleitet | William Blair | Outperform |
| 2023-08-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-07-03 | Eingeleitet | BofA Securities | Buy |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-01-27 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-12-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-22 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2021-05-04 | Eingeleitet | Jefferies | Buy |
| 2021-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2021-05-04 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Onkure Therapeutics Inc Aktie (OKUR) Neueste Nachrichten
What hedge fund activity signals for OnKure Therapeutics Inc. stock2026 world cup usa national team quarterfinals key players high defensive line odds analysis insights - ulpravda.ru
Will OnKure Therapeutics Inc. stock attract more institutional investors2026 world cup usa national team third place match playmakers high defensive line expert forecast expert opinion - ulpravda.ru
Quarterly Recap: How British Land Company PLC BLD stock expands through international marketsFed Meeting & AI Forecasted Entry and Exit Points - moha.gov.vn
Bull Bear: Why OnKure Therapeutics Inc stock is a must watch in 2025Weekly Profit Report & Low Risk Entry Point Tips - moha.gov.vn
OnKure Therapeutics, Inc. (NASDAQ:OKUR) Short Interest Up 25.6% in December - Defense World
How OnKure Therapeutics Inc. stock performs after earningsPrice Action Analysis & Free Unlock Rapid Growth Potential - bollywoodhelpline.com
OnKure Therapeutics CFO Leverone sells $896 in stock By Investing.com - Investing.com Nigeria
OnKure Therapeutics Inc Stock Analysis and ForecastDay Trading Setups & Identify Winning Stocks - earlytimes.in
OnKure Therapeutics CEO Saccomano sells $258 in stock By Investing.com - Investing.com South Africa
OnKure Therapeutics CFO Leverone sells $896 in stock - Investing.com
OnKure Therapeutics CEO Saccomano sells $258 in stock - Investing.com India
Is OnKure Therapeutics Inc. stock a safe investment in uncertain markets2025 Geopolitical Influence & AI Based Trade Execution Alerts - Улправда
Aug Technicals: What analyst consensus says on UYSCU stockJuly 2025 Macro Moves & Safe Entry Trade Reports - moha.gov.vn
Can OnKure Therapeutics Inc. stock sustain free cash flow growthWeekly Stock Recap & Precise Swing Trade Alerts - Улправда
Can OnKure Therapeutics Inc. stock rebound after recent weaknessWeekly Market Outlook & Free Community Consensus Stock Picks - Улправда
How OnKure Therapeutics Inc. stock performs in weak economy2025 Major Catalysts & Long-Term Growth Plans - DonanımHaber
Why OnKure Therapeutics Inc. stock could rally in 2025Wall Street Watch & Weekly High Conviction Trade Ideas - Bölüm Sonu Canavarı
Why OnKure Therapeutics Inc. stock is considered a top pick2025 Market Trends & Free Expert Verified Stock Movement Alerts - Улправда
Why OnKure Therapeutics Inc. stock is a must watch in 2025July 2025 Outlook & AI Forecasted Stock Moves - DonanımHaber
CEO Change: How OnKure Therapeutics Inc. stock performs in high volatility marketsMarket Volume Report & Capital Protection Trade Alerts - Улправда
Aug PostEarnings: Why OnKure Therapeutics Inc. stock is considered a top pickJuly 2025 Market Mood & Risk Managed Investment Signals - Улправда
Is OnKure Therapeutics Inc. stock a buy on dipsMarket Risk Summary & Accurate Intraday Trade Tips - Улправда
OnKure Therapeutics, Inc.(NasdaqGM: OKUR) dropped from NASDAQ Biotechnology Index - marketscreener.com
OnKure Therapeutics Earnings Notes - Trefis
Acorn Capital Advisors LLC Grows Position in OnKure Therapeutics, Inc. $OKUR - Defense World
Why OnKure Therapeutics Inc stock could rally in 2025Weekly Volume Report & Reliable Entry Point Trade Alerts - moha.gov.vn
Ready to Jump After Recent Trade: OnKure Therapeutics Inc (OKUR) - Setenews
Why OnKure Therapeutics Inc. stock could outperform in 2025CPI Data & Weekly Breakout Stock Alerts - Newser
OnKure Therapeutics (OKUR) Stock Analysis Report | Financials & Insights - Benzinga
Will OnKure Therapeutics Inc. stock sustain high P E ratiosMarket Performance Recap & Capital Efficient Trade Techniques - Newser
Published on: 2025-11-27 20:24:24 - BỘ NỘI VỤ
OnKure Therapeutics, Inc. (NASDAQ:OKUR) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
[424B3] OnKure Therapeutics, Inc. Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
What margin trends mean for OnKure Therapeutics Inc. stockGDP Growth & Weekly Chart Analysis and Guides - newser.com
Why OnKure Therapeutics Inc. stock is a value investor pickJuly 2025 Trends & Short-Term Swing Trade Alerts - newser.com
How rising interest rates impact OnKure Therapeutics Inc. stockPortfolio Value Summary & Verified Swing Trading Watchlist - newser.com
Will OnKure Therapeutics Inc. stock remain a Wall Street favorite2025 Analyst Calls & Long-Term Safe Investment Plans - newser.com
How OnKure Therapeutics Inc. stock reacts to inflationary pressuresWeekly Profit Summary & Long Hold Capital Preservation Tips - newser.com
Finanzdaten der Onkure Therapeutics Inc-Aktie (OKUR)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):